VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
ADVMAdverum Biotechnologies, Inc.
$4.36$96M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksADVMEarnings History

ADVM logoAdverum Biotechnologies, Inc. (ADVM) Earnings History

Net Loss

13 years of earnings data (2012–2024) · Currently unprofitable on a TTM basis

TTM Net Income
-$204M
● Net Loss
TTM EPS (Diluted)
$-8.70
Per share, diluted
YoY EPS Growth
-227.7%
Declining
Net Margin
-13092.7%
After-tax profitability
EPS Growth Rate (CAGR)
1YN/A
3YN/A
5YN/A
10YN/A
Operating Margin-13915.9%
Gross Margin100.0%
Return on Equity-189.8%
Return on Assets-78.0%
Record Annual Net Income-$2MFY2012
Record Quarterly EPS$-0.08Q1 2014
Consecutive Profitable Years0years
Q3 2025
Net Income-$48M
EPS (Diluted)$-2.03
YoY Growth-227.7%Declining
QoQ Growth+3.1%Solid

Loading earnings history...

Adverum Biotechnologies, Inc. (ADVM) Earnings Overview

As of June 22, 2026, Adverum Biotechnologies, Inc. (ADVM) reported trailing twelve-month net income of -$204M, reflecting -227.7% year-over-year growth. The company earned $-8.70 per diluted share over the past four quarters, with a net profit margin of -13092.7%.

Looking at the long-term picture, ADVM's historical earnings data spans multiple years. The company achieved its highest annual net income of -$2M in fiscal 2012.

Adverum Biotechnologies, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →

Compared to peers including OCGN (-$72M net income, -1537.4% margin), EDIT (-$109M net income, -395.0% margin), KRYS ($225M net income, 52.6% margin), ADVM has room to improve margins relative to the peer group. Compare ADVM vs OCGN →

ADVM Earnings vs Peers

Earnings metrics vs comparable public companies

CompanyTTM Net IncomeTTM EPSNet MarginROEYoY GrowthCompare
ADVM logoADVMCurrent
-$204M$-8.70-13092.7%-189.8%-227.7%—
OCGN logoOCGN
-$72M$-0.22-1537.4%-776.9%-15.0%
EDIT logoEDIT
-$109M$-1.11-395.0%-198.1%+37.5%
KRYS logoKRYS
$225M$7.3852.6%18.9%+128.0%
RARE logoRARE
-$609M$-6.06-85.4%-607.5%+7.3%
BMRN logoBMRN
$269M$1.3610.8%5.9%-18.6%
Best in group
Lowest in group

ADVM Historical Earnings Data (2012–2024)

13 years
Fiscal Year Net Income YoY % Operating Income EPS (Diluted) Net Margin Op. Margin
2024-$131M-7.2%-$139M$-6.62-13092.7%-13915.9%
2023-$122M+21.0%-$129M$-2.02-3392.1%-3581.7%
2022-$155M-6.2%-$157M$-2.67--
2021-$146M-23.9%-$146M$-1.48-1940.5%-1948.3%
2020-$118M-82.2%-$118M$-1.26--
2019-$64M+11.2%-$69M$-0.87-25794.4%-27418.0%
2018-$73M-29.4%-$78M$-1.18-4505.4%-4843.7%
2017-$56M+50.6%-$59M$-1.29-3036.6%-3182.6%
2016-$114M-139.7%-$115M$-3.14-7817.7%-7923.3%
2015-$47M-86.8%-$48M$-1.84-2046.3%-2062.2%
2014-$25M-381.5%-$24M$-1.12-4441.3%-4266.1%
2013-$5M-191.3%-$3M$-0.25-1099.2%-719.6%
2012-$2M--$2M$-0.09-6036.7%-6053.3%

Download Data

Export ADVM earnings history in CSV or JSON format

Free sign-in required to download data

Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

14+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

ADVM — Frequently Asked Questions

Quick answers to the most common questions about buying ADVM stock.

What is ADVM earnings per share (EPS)?

ADVM trailing twelve-month (TTM) diluted EPS is $-8.70, reflecting -227.7% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2012 to 2024 is available in the table on this page.

What is Adverum Biotechnologies, Inc.'s net income?

Adverum Biotechnologies, Inc. (ADVM) trailing twelve-month net income is $-204M as of 2024. Earnings declined -227.7% year-over-year.

Is ADVM profitable?

ADVM is not currently profitable on a TTM basis, reporting a net loss of $-204M. Net margin is -13092.7%. Investors should monitor for a return to profitability.

What is ADVM's earnings growth rate?

ADVM compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2012 to 2024.

What are ADVM's profit margins?

Adverum Biotechnologies, Inc. net profit margin is -13092.7%, operating margin is -13915.9%, and gross margin is +100.0%. Below-average margins reflect competitive or cost pressures. Return on Equity is -189.8%.

Is ADVM growing earnings?

ADVM earnings are declining — EPS fell -227.7% year-over-year. TTM net income dropped to $-204M. This contrasts with the 5-year CAGR of N/A.

What was ADVM's best earnings year?

Adverum Biotechnologies, Inc.'s highest annual net income on record is $-2M, achieved in fiscal year 2012. Earnings history on this page spans 2012 to 2024 and includes all annual and quarterly figures.

What were ADVM's earnings last quarter?

ADVM's most recent reported quarter was Q3 2025. Net income was $-48M with diluted EPS of $-2.03. For a full breakdown of all quarters, see the quarterly earnings table on this page.

ADVM Earnings Over Time (2012–2024)

Net income & EPS — annual and quarterly view